Jeroen V Koomen

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 15

Top Topics

Diabetic Nephropathy

Kidney Transplantation

Top Venues

Diabetes, obesity & metabolism

British journal of clinical pharmacology

International journal of molecular sciences

Clinical pharmacokinetics

This page only lists publications with an associated author ORCID identifier.

Publications

Omnia Salah Heikal, Patrick F van Rheenen, Daan J Touw, Jos G W Kosterink, Marina Maurer, Jeroen V Koomen, Pierre Chelle, Paola Mian
Infliximab in paediatric inflammatory bowel disease: External evaluation of population pharmacokinetic models. British journal of clinical pharmacology (2024)
Omnia Salah Heikal, Patrick F van Rheenen, Daan J Touw, Jos G W Kosterink, Marina Maurer, Jeroen V Koomen, Pierre Chelle, Paola Mian
Infliximab in paediatric inflammatory bowel disease: External evaluation of population pharmacokinetic models. British journal of clinical pharmacology 90 (9) (2024)
Omnia Salah Heikal, Patrick F van Rheenen, Daan J Touw, Jos G W Kosterink, Marina Maurer, Jeroen V Koomen, Pierre Chelle, Paola Mian
Infliximab in paediatric inflammatory bowel disease: External evaluation of population pharmacokinetic models. British journal of clinical pharmacology 90 (9) (2024)
G J Julia Huisman, Nora A Spraakman, Jeroen V Koomen, A Marrit Talsma, Robert A Pol, Stefan P Berger, Henri G D Leuvenink, Michel M R F Struys, Gertrude J Nieuwenhuijs-Moeke
Urinary Biomarkers in a Living Donor Kidney Transplantation Cohort-Predictive Value on Graft Function. International journal of molecular sciences 24 (6) (2023)
G J Julia Huisman, Nora A Spraakman, Jeroen V Koomen, A Marrit Talsma, Robert A Pol, Stefan P Berger, Henri G D Leuvenink, Michel M R F Struys, Gertrude J Nieuwenhuijs-Moeke
Urinary Biomarkers in a Living Donor Kidney Transplantation Cohort-Predictive Value on Graft Function. International journal of molecular sciences 24 (6) (2023)
Marie Kroneisl, Nora A Spraakman, Jeroen V Koomen, Zeinab Hijazi, Femke H Hoogstra-Berends, Henri G D Leuvenink, Michel M R F Struys, Robert H Henning, Gertrude J Nieuwenhuijs-Moeke
Peri-Operative Kinetics of Plasma Mitochondrial DNA Levels during Living Donor Kidney Transplantation. International journal of molecular sciences 24 (17) (2023)
Jeroen V Koomen, Tim J Knobbe, Tanja R Zijp, Daan Kremer, C Tji Gan, Erik A M Verschuuren, Stephan J L Bakker, Daan J Touw, Pieter J Colin, null null
A Joint Pharmacokinetic Model for the Simultaneous Description of Plasma and Whole Blood Tacrolimus Concentrations in Kidney and Lung Transplant Recipients. Clinical pharmacokinetics (2023)
G J Julia Huisman, Nora A Spraakman, Jeroen V Koomen, A Marrit Talsma, Robert A Pol, Stefan P Berger, Henri G D Leuvenink, Michel M R F Struys, Gertrude J Nieuwenhuijs-Moeke
Urinary Biomarkers in a Living Donor Kidney Transplantation Cohort-Predictive Value on Graft Function. International journal of molecular sciences 24 (6) (2023)
Tessa C C Jaspers, Charlotte E Meijer, Louis Jean Vleming, Casper F M Franssen, Jeroen Diepstraten, Michael V Lukens, Patricia Maria Lucia Adriana van den Bemt, Barbara Maat, Nakisa Khorsand, Daniel J Touw, Jeroen V Koomen
Optimising the Nadroparin Dose for Thromboprophylaxis During Hemodialysis by Developing a Population Pharmacodynamic Model Using Anti-Xa Levels. Clinical pharmacokinetics 61 (11) (2022)
J David Smeijer, Jeroen V Koomen, Donald E Kohan, John J V McMurray, George L Bakris, Ricardo Correa-Rotter, Fan Fan Hou, Dalane W Kitzman, Hirofumi Makino, Gert Mayer, Michal Nowicki, Vlado Perkovic, Peter Rossing, Sheldon Tobe, Hans-Henrik Parving, Dick de Zeeuw, Hiddo J L Heerspink
Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long-Term Response to Atrasentan in Patients With Diabetic Kidney Disease. Clinical pharmacology and therapeutics 112 (5) (2022)
Marjolein Y A M Kroonen, Jeroen V Koomen, Sergei I Petrykiv, Gozewijn D Laverman, Hiddo J Lambers Heerspink, Jasper Stevens
Exposure-response relationships for the sodium-glucose co-transporter-2 inhibitor dapagliflozin with regard to renal risk markers. Diabetes, obesity & metabolism 22 (6) (2020)
Jeroen V Koomen, Jasper Stevens, George L Bakris, Ricardo Correa-Rotter, Fan Fan Hou, Dalane W Kitzman, Donald Kohan, Hirofumi Makino, John Joseph Valentine McMurray, Hans-Henrik Parving, Vlado Perkovic, Sheldon W Tobe, Dick de Zeeuw, Hiddo J Lambers Heerspink
Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial. Diabetes, obesity & metabolism 23 (2) (2020)
Jeroen V Koomen, Jasper Stevens, Hiddo J Lambers Heerspink
Exposure-response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials. British journal of clinical pharmacology 86 (11) (2020)
Jeroen V Koomen, Hiddo J Lambers Heerspink, Ilse C Schrieks, Gregory G Schwartz, A Michael Lincoff, Stephen J Nicholls, Anders Svensson, Hans Wedel, Arlette Weichert, Diederick E Grobbee, Jasper Stevens
Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial. Diabetes, obesity & metabolism 22 (1) (2019)
Jeroen V Koomen, Jasper Stevens, Nael M Mostafa, Hans-Henrik Parving, Dick de Zeeuw, Hiddo J Lambers Heerspink
Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight. Diabetes, obesity & metabolism 20 (8) (2018)